Sinopharm Group Co. Ltd. — Board/Management Information 2024

Sep 15, 2024

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [298 x 120] intentionally omitted <==

(A joint stock limited company incorporated in the People’s Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司) (Stock Code: 01099)

ANNOUNCEMENT CHANGE IN COMPOSITION OF BOARD COMMITTEES

Reference is made to the announcement of poll results of the extraordinary general meeting of Sinopharm Group Co. Ltd. (the “ Company ”) dated 13 September 2024 in relation to, among others, the appointment of Mr. Zhao Bingxiang as a non-executive director (the “ Director ”) of the Company and the appointment of Mr. Lian Wanyong as an executive Director.

The board (the “ Board ”) of Directors of the Company announces that Mr. Zhao Bingxiang, a non-executive Director, has been appointed as the chairman of the nomination committee of the Board, the chairman of the strategy and investment committee of the Board (the “ Strategy and Investment Committee ”) and a member of the legal and compliance and environmental, social and governance committee of the Board (the “ Legal and Compliance and Environmental, Social and Governance Committee ”), and Mr. Lian Wanyong, an executive Director, has been appointed as a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee, all of which with effect from 14 September 2024.

By order of the Board Sinopharm Group Co. Ltd. Zhao Bingxiang Chairman

Shanghai, the PRC 14 September 2024

As at the date of this announcement, the executive Director is Mr. Lian Wanyong; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu , Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

1